Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 47Triple Negative Breast Neoplasms 25Ovarian Neoplasms 8Neoplasm Metastasis 8Melanoma 8Prostatic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Carcinoma, Merkel Cell 3Lung Neoplasms 2Kidney Neoplasms 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Thyroid Neoplasms 1

Interventions

poly ICLC 1pembrolizumab 1enzalutamide 1durvalumab 1atezolizumab 1advexin 1Nivolumab 1High-Intensity Focused Ultrasound Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × durvalumab × Breast × Clear all
NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡